Role of Fyn Kinase Inhibitors in Switching Neuroinflammatory Pathways.


Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
2022
Historique:
received: 30 07 2021
revised: 18 11 2021
accepted: 22 11 2021
pubmed: 24 12 2021
medline: 19 8 2022
entrez: 23 12 2021
Statut: ppublish

Résumé

Fyn kinase is a member of the Src non-receptor tyrosine kinase family. Fyn is involved in multiple signaling pathways extending from cell proliferation and differentiation to cell adhesion and cell motility, and it has been found to be overexpressed in various types of cancers. In the central nervous system, Fyn exerts several different functions such as axon-glial signal transduction, oligodendrocyte maturation, and myelination, and it is implicated in neuroinflammatory processes. Based on these premises, Fyn emerges as an attractive target in cancer and neurodegenerative disease therapy, particularly Alzheimer's disease (AD), based on its activation by Aβ via cellular prion protein and its interaction with tau protein. However, Fyn is also a challenging target since the Fyn inhibitors discovered so far, due to the relevant homology of Fyn with other kinases, suffer from off-target effects. This review covers the efforts performed in the last decade to identify and optimize small molecules that effectively inhibit Fyn, both in enzymatic and in cell assays, including drug repositioning practices, as an opportunity for therapeutic intervention in neurodegeneration.

Identifiants

pubmed: 34939537
pii: CMC-EPUB-119579
doi: 10.2174/0929867329666211221153719
doi:

Substances chimiques

Proto-Oncogene Proteins c-fyn EC 2.7.10.2

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

4738-4755

Subventions

Organisme : Italian Ministry of University and Research (MIUR), PRIN 2017
ID : 2017MT3993_007

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Giambattista Marotta (G)

Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, via Belmeloro 6, Bologna, 40126, Italy.

Filippo Basagni (F)

Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, via Belmeloro 6, Bologna, 40126, Italy.

Michela Rosini (M)

Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, via Belmeloro 6, Bologna, 40126, Italy.

Anna Minarini (A)

Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, via Belmeloro 6, Bologna, 40126, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH